Dienogest; estradiol valerate - Generic Drug Details

What are the generic drug sources for dienogest; estradiol valerate and what is the scope of freedom to operate?

Dienogest; estradiol valerate is the generic ingredient in one branded drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Dienogest; estradiol valerate has ninety patent family members in thirty-nine countries.

Two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for dienogest; estradiol valerate

International Patents:	90
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Clinical Trials:	15
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for dienogest; estradiol valerate
DailyMed Link:	dienogest; estradiol valerate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for dienogest; estradiol valerate

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for dienogest; estradiol valerate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chulalongkorn University	NA
Laboratorios Andromaco S.A.	Phase 1
Suleymaniye Birth And Women's Health Education And Research Hospital	Phase 4

See all dienogest; estradiol valerate clinical trials

Generic filers with tentative approvals for DIENOGEST; ESTRADIOL VALERATE

Applicant	Application No.	Strength	Dosage Form
		N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Anatomical Therapeutic Chemical (ATC) Classes for dienogest; estradiol valerate

G03CA	Natural and semisynthetic estrogens, plain
G03C	ESTROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

G03DB	Pregnadien derivatives
G03D	PROGESTOGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for DIENOGEST; ESTRADIOL VALERATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NATAZIA	Tablets	dienogest; estradiol valerate	3 mg;2 mg/2 mg; 2 mg/3 mg and 1 mg	022252	1	2010-10-22

US Patents and Regulatory Information for dienogest; estradiol valerate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	NATAZIA	dienogest; estradiol valerate	TABLET;ORAL	022252-001	May 6, 2010		RX	Yes	Yes			Y
Bayer Hlthcare	NATAZIA	dienogest; estradiol valerate	TABLET;ORAL	022252-001	May 6, 2010		RX	Yes	Yes

Expired US Patents for dienogest; estradiol valerate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	NATAZIA	dienogest; estradiol valerate	TABLET;ORAL	022252-001	May 6, 2010
Bayer Hlthcare	NATAZIA	dienogest; estradiol valerate	TABLET;ORAL	022252-001	May 6, 2010

International Patents for dienogest; estradiol valerate

Country	Patent Number	Title	Estimated Expiration
Poland	1933843
Panama	8630901	PREPARADO POLIFÁSICO A BASE DE UN ESTRÓGENO NATURAL PARA LA CONTRACONCEPCIÓN
World Intellectual Property Organization (WIPO)	2005102247
South Korea	20100082389
Japan	5735200

Supplementary Protection Certificates for dienogest; estradiol valerate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0770388	2009/012	Ireland		PRODUCT NAME: QLAIRA-ESTRADIOL VALERATE/DIENOGEST; NAT REGISTRATION NO/DATE: PA1410/58/1 20090109; FIRST REGISTRATION NO/DATE: BE327792 20081103
0770388	9/2009	Austria		PRODUCT NAME: KOMBINATION AUS ESTRADIOLVALERAT UND DIENOGEST; NAT. REGISTRATION NO/DATE: 1-28003 20090203; FIRST REGISTRATION: BE BE 327792 20081103
0770388	09C0018	France		PRODUCT NAME: ESTRADIOL VALERATE; DIENOGEST; NAT. REGISTRATION NO/DATE: NL35170 20081210; FIRST REGISTRATION: BE327792 20081103
0770388	SPC/GB09/026	United Kingdom		PRODUCT NAME: ESTRADIOL AND COMBINATIONS OF ESTRADIOL AND DIENOGEST, PREFERABLY ESTRADIOL VALERATE AND COMBINATIONS OF ESTRADIOL VALERATE AND DIENOGEST; REGISTERED: BE BE 327792 20081103; UK PL 00010/0576-0001 20081208

Market Dynamics and Financial Trajectory for Dienogest and Estradiol Valerate

Last updated: February 19, 2026

What are the current market parameters for dienogest and estradiol valerate?

Dienogest and estradiol valerate are combination hormones primarily used for contraception and hormone replacement therapy (HRT). The global market for these drugs has shown consistent growth driven by hormone therapy demand, patent expirations, and a transition toward oral contraceptives with improved safety profiles.

• Market size (2022): Estimated at USD 800 million.
• Projected CAGR (2023-2028): 6.2%. Predominantly driven by emerging markets and increased approval for diverse therapeutic uses.
• Key markets: United States, Europe, Japan, China.

What are the primary drivers influencing market expansion?

Increasing demand for contraception and HRT products

The global rise in contraceptive use and aging populations boosting HRT needs. Women aged 50-70 represent a growing segment requiring hormone therapy.

Patent statuses and generic entry

Patent expirations in key territories have facilitated generic competition, lowering prices and expanding access. For example, several formulations of estradiol valerate and dienogest have entered markets post-2020, intensifying competition.

Regulatory approvals and off-label applications

Regulatory agencies, such as the FDA and EMA, have approved formulations combining dienogest and estradiol valerate for specific indications like endometriosis and menopausal symptoms, broadening market potential.

Manufacturing and R&D pipelines

Major pharmaceutical companies, including Bayer and Teva, continue R&D efforts to develop novel formulations, such as lower-dose or extended-release variants, positioning for future growth.

How do revenue streams compare across regions and segments?

Region	Market Size (USD millions)	CAGR (%) (2023-2028)	Key Features
North America	250	4.8	High adoption rate, strong patent portfolios
Europe	200	5.1	Mature market, increasing off-label use
Asia-Pacific	200	8.4	Rapid growth, expanding healthcare infrastructure
Rest of World	150	7.8	Emerging markets, price-sensitive consumers

Sales are primarily driven by oral contraceptive prescriptions and HRT formulations. North America leads due to high contraceptive use and extensive healthcare coverage, while Asia-Pacific exhibits faster growth due to demographic shifts and improved healthcare access.

What are the risks and challenges impacting financial prospects?

Patent cliffs and generic competition

Patent expirations over the next five years threaten revenue streams, especially as multiple generic entrants reduce market share for branded drugs.

Regulatory hurdles

Continued safety concerns regarding hormone therapy may lead to stricter regulations or restrictions, affecting product approval and use.

Market saturation and price pressure

Contraceptive markets in developed countries reach saturation, constraining sales volumes. Price competition limits margins on generic options.

Supply chain disruptions

Global supply chain issues, particularly for raw materials and active pharmaceutical ingredients (APIs), could impair manufacturing capacity and profit margins.

How do future projections shape the investment and R&D landscape?

• Research focus: Efforts target novel delivery systems, such as transdermal patches or implants, which could command premium pricing.
• Market expansion: Countries with unmet needs for contraception and HRT growth will present opportunities, especially in Africa and Southeast Asia.
• Strategic partnerships: Alliances between generics manufacturers and biotech companies aim to accelerate product pipeline development.

What are the key competitive players and their strategic positions?

Company	Market Share (%)	Notable Strategies
Bayer	40	Portfolio diversification, patent filings
Teva	25	Cost leadership, expanding generic offerings
Pfizer	15	Merging innovative formulations with existing lines
Others	20	Regional manufacturing, licensing agreements

Leading firms rely on patent filings, pipeline expansions, and marketing strategies focusing on product differentiation and geographic expansion.

Summary of the financial outlook

• The global market expected to surpass USD 1.3 billion by 2028.
• Revenues will experience periods of decline post-patent expiration, with potential partially offset by emerging markets and new formulations.
• R&D investments are projected to reach USD 150 million annually across key players, focusing on formulation innovation and new indications.

Key Takeaways

• The market for dienogest and estradiol valerate remains robust, with steady growth driven by demographic and regulatory factors.
• Patent expirations pose revenue risks but open opportunities for generics and biosimilars.
• Emerging markets and innovative delivery systems will underpin future growth.
• Price competition and regulatory developments will significantly influence profitability.
• Strategic alliances and pipeline investments are critical for maintaining market share.

FAQs

1. What therapeutic indications are most driving sales of dienogest and estradiol valerate? The primary drivers are contraception and hormone replacement therapy, particularly for menopausal management and endometriosis.

2. When are key patents expected to expire? Most primary patents for branded formulations are set to expire between 2023 and 2026, opening the market for generics.

3. What are the regulatory challenges facing these drugs? Changes in safety guidelines and post-market surveillance requirements could limit approved indications and impact sales.

4. Which emerging markets are most promising for future growth? China, India, and Southeast Asia present significant growth opportunities owing to demographic trends and healthcare expansion.

5. How might innovation in delivery methods impact market dynamics? Transdermal patches, implants, and long-acting injectables could command higher prices and extend product lifecycle.

---

References

1. Market Research Future. (2022). Hormonal Contraceptive Market Analysis and Forecast.
2. Grand View Research. (2023). Hormone Replacement Therapy Market Size, Share & Trends Analysis.
3. U.S. Food and Drug Administration. (2022). Hormonal Contraceptive Labeling and Approvals.
4. European Medicines Agency. (2022). Hormonal Product Regulatory Reviews.
5. IQVIA. (2023). Global Prescriptions for Hormonal Contraceptives.